Hopital Cardiologique

The team at Hopital Cardiologique is evaluating innovative approaches to lower the risk of heart attack and stroke in patients with high cardiovascular risk. Studies include the use of novel lipid‑lowering antibodies and oral agents that may improve heart muscle recovery after an acute event.

• Evaluation of long‑term safety of lipid‑lowering antibodies
• Assessment of heart‑remodeling therapies after myocardial infarction
• Investigation of novel anticoagulant strategies for secondary prevention
• Comparative effectiveness of metabolic agents in cardiac patients

These trials aim to reduce cardiovascular events and improve cardiac function by testing new therapies and refining existing treatment pathways.

A broad oncology program focuses on advanced lung cancers and other solid tumors, testing cutting‑edge targeted agents such as non‑small cell lung cancer therapies and drugs directed at KRAS G12C mutations. Researchers also explore antibody‑drug conjugates for HER2‑positive disease.

• Development of targeted therapy combinations for lung cancer
• Evaluation of antibody‑drug conjugates in solid tumors
• KRAS‑directed inhibitor studies across multiple cancer types
• Integration of immunotherapy with novel agents

The purpose of these studies is to improve response rates and survival for patients with difficult‑to‑treat cancers by introducing more precise and effective treatments.

The site conducts trials aimed at chronic lung conditions, including cystic fibrosis and severe asthma with an eosinophilic phenotype, as well as preventative strategies against COVID‑19. Efforts are directed toward long‑term disease control and reduction of acute exacerbations.

• Long‑term modulators for cystic fibrosis patients
• Biologic therapies for eosinophilic asthma
• Antibody prophylaxis to prevent symptomatic COVID‑19
• Novel treatment regimens for advanced lung cancer subtypes

These investigations seek to enhance quality of life, decrease hospitalizations, and provide new preventive options for respiratory illnesses.

Studies address the intersection of metabolic health and cardiovascular outcomes, evaluating agents such as dapagliflozin for their ability to support heart function after myocardial injury and to manage metabolic risk factors.

• Effects of SGLT2 inhibitors on cardiac remodeling post‑MI
• Metabolic management strategies in high‑risk cardiac patients
• Interaction of nutrition‑related pathways with heart disease
• Assessment of metabolic endpoints in cardiovascular trials

The goal is to integrate metabolic therapies into cardiovascular care, improving overall patient outcomes and reducing disease progression.